ImmVira has inaugurated a pilot-scale production line in Shenzhen, China and initiated its in-house production of next-generation oncolytic viruses (OV) used for IND applications and Phase I/II clinical trials. Leveraging a strategy of dual in-house manufacturing and CDMO operations, ImmVira says it can continue to innovate CMC techniques while concurrently improving production efficiency with the goal of expediting the advancement of clinical trials for its pipelines.   The company said the lau...